AVXL. It's been steadily on the rise since it was trading at 15 cents a couple months ago. It's now a dollar ten. Phase 2 trials for its Alzheimer's drug had good results which led to the spike. Bigger news at the end of the year. Big potential but who knows there's tons of these small caps in the biotech sector that have failed.